Bone Biologics EBIT par action

Que fait Bone Biologics ? Bone Biologics Corp. generates revenue through the development and sale of its NELL-1/DBM Fusion Device, a bone regeneration product for spinal fusion procedures. The device combines NELL-1, a recombinant human protein, with demineralized bone matrix (DBM) to provide targeted bone regeneration control. Medical professionals use the product for spine implants, non-union trauma cases, and osteoporosis treatments. The company's platform technology, centered on NELL-1, is developed through laboratory and animal research to support applications in bone void filling and skeletal regeneration. The firm focuses on osteopromotive applications using NELL-1, a skeletal-specific growth factor proven in laboratory models to replicate human growth and development. NELL-1 is marketed as a bone void filler and is integrated into spinal fusion devices. The company's revenue streams derive from the commercialization of NELL-1-based products targeting orthopedic and spinal surgery markets. Medical device companies and healthcare providers purchase the NELL-1/DBM Fusion Device for clinical use in bone regeneration procedures. Bone Biologics est l'une des entreprises les plus populaires sur Eulerpool.